Interpace Diagnostics Group, Inc. (75) | Note Agreements (6)

Recent Contracts

Subordinated Convertible Promissory Note to BroadOak Fund V, L.P., dated May 5, 2022 (Filed With SEC on May 10, 2022)
Amendment to Secured Promissory Note dated May 10, 2021 with Ampersand 2018 Limited Partnership (Filed With SEC on August 11, 2021)
Amendment to Secured Promissory Note dated May 10, 2021 with1315 Capital II, L.P (Filed With SEC on August 11, 2021)
Promissory Note entered into between the Company and Ampersand 2018 Limited Partnership, dated January 7, 2021 (Filed With SEC on May 11, 2021)
Promissory Note entered into between the Company and 1315 Capital II, L.P, dated January 7, 2021 (Filed With SEC on May 11, 2021)
Subordinated Seller Note of Interpace BioPharma, Inc., dated July 15, 2019, in favor of Cancer Genetics, Inc (Filed With SEC on July 19, 2019)